TY - JOUR
T1 - Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms
T2 - An international multicentre study
AU - Aguado-Barrera, Miguel E.
AU - Lopez-Pleguezuelos, Carlos
AU - Gómez-Caamaño, Antonio
AU - Calvo-Crespo, Patricia
AU - Taboada-Valladares, Begoña
AU - Azria, David
AU - Boisselier, Pierre
AU - Briers, Erik
AU - Chan, Clara
AU - Chang-Claude, Jenny
AU - Coedo-Costa, Carla
AU - Crujeiras-González, Ana
AU - Cuaron, John J.
AU - Defraene, Gilles
AU - Elliott, Rebecca M.
AU - Faivre-Finn, Corinne
AU - Franceschini, Marzia
AU - Fuentes-Rios, Olivia
AU - Galego-Carro, Javier
AU - Gutiérrez-Enríquez, Sara
AU - Heumann, Philipp
AU - Higginson, Daniel S.
AU - Johnson, Kerstie
AU - Lambrecht, Maarten
AU - Lang, Philippe
AU - Lievens, Yolande
AU - Mollà, Meritxell
AU - Ramos, Mónica
AU - Rancati, Tiziana
AU - Rattay, Tim
AU - Rimner, Andreas
AU - Rosenstein, Barry S.
AU - Sangalli, Claudia
AU - Seibold, Petra
AU - Sperk, Elena
AU - Stobart, Hilary
AU - Symonds, Paul
AU - Talbot, Christopher J.
AU - Vandecasteele, Katrien
AU - Veldeman, Liv
AU - Ward, Tim
AU - Webb, Adam
AU - Woolf, David
AU - de Ruysscher, Dirk
AU - West, Catharine M.L.
AU - Vega, Ana
AU - REQUITE consortium
N1 - Funding Information:
We would like to express our gratitude to all participants who participated in the REQUITE study, as well as to the dedicated REQUITE staff, healthcare professionals, and researchers involved at the following hospitals: Ghent University Hospital, Gent, Belgium; University Hospitals Leuven, Leuven, Belgium; Department of Radiation Oncology, Montpellier Cancer Institute, Universit\u00E9 Montpellier, Montpellier, France; Candiolo Cancer Institute\u2013FPO, IRCCS, Candiolo, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Vall d'Hebron Institut d'Oncologia, Barcelona, Spain; MAASTRO Clinic, Maastricht; The Netherlands; Queen Elizabeth Hospital Birmingham, Birmingham, UK; Derby Teaching Hospitals NHS Foundation Trust, Derby; UK; University Hospitals of Leicester NHS Trust, Leicester, UK; The University of Manchester, Manchester; UK; Nottingham University Hospitals NHS Trust, Nottingham, UK; Mount Sinai Hospital, NY, USA; Memorial Sloan Kettering Cancer Center, NY, USA; Salford Royal NHS Trust, Salford, UK. This research project was made possible through the access granted by the Galician Supercomputing Center (CESGA) to its supercomputing infrastructure. The supercomputer FinisTerrae III and its permanent data storage system have been funded by the Spanish Ministry of Science and Innovation, the Galician Government and the European Regional Development Fund (ERDF). VHIO acknowledge: the Cellex Foundation for providing research facilities, the CERCA Programme from the Generalitat de Catalunya for their institutional support and the Agencia Estatal de Investigaci\u00F3n for their financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033).
Funding Information:
Contract grant sponsor Ana Vega: supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (PI22/00589, PI19/01424; INT24/00023; DTS24/00083); the ERAPerMed JTC2018 funding (AC18/00117); the Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the AECC (PRYES211091VEGA).
Funding Information:
REQUITE received funding from the European Union's Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 601826.
Funding Information:
Sara Guti\u00E9rrez-Enriquez is supported by the Government of Catalonia (2021SGR01112).
Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - Background and purpose: We investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies. Materials and methods: Data from 515 participants in the REQUITE study were analysed. Five symptoms (cough, dyspnoea, bronchopulmonary haemorrhage, chest wall pain, dysphagia) were evaluated both before and after radiotherapy. Agreement between healthcare professionals and people with lung cancer was quantified using Gwet's-AC2 coefficient. The influence of clinical variables, comorbidities, and quality-of-life outcomes on agreement was examined through stratified analyses. Results: We found varying levels of agreement between healthcare professionals and people with lung cancer. Bronchopulmonary haemorrhage and dysphagia exhibited very good agreement (meanAC2 > 0.81), while cough and chest wall pain showed substantial agreement (meanAC2 = 0.64 and 0.76, respectively). Dyspnoea had the lowest agreement (meanAC2 = 0.59), with prior chemotherapy significantly reducing agreement levels. Chronic obstructive pulmonary disease (COPD) and early cancer stages also contributed to discrepancies in dyspnoea assessments. Regarding quality-of-life, the most relevant factor was fatigue, which reduced agreement in the assessment of dyspnoea (AC2 = 0.55 vs 0.70), dysphagia (AC2 = 0.48 vs 0.69), cough (AC2 = 0.58 vs 0.82), and chest wall pain (AC2 = 0.77 vs 0.91). Conclusions: Our findings indicate strong alignment between healthcare professionals’ and people with lung cancer evaluations of observable treatment-related symptoms, but less consistency for subjective symptoms such as dyspnoea. Factors such as prior chemotherapy, COPD, and cancer stage should be considered when interpreting symptom assessments. Furthermore, our study underscores the importance of integrating quality-of-life considerations, particularly fatigue, into symptom evaluations to mitigate potential biases in symptom perception.
AB - Background and purpose: We investigate discrepancies in the assessment of treatment-related symptoms in lung cancer between healthcare professionals and patients, and factors contributing to these discrepancies. Materials and methods: Data from 515 participants in the REQUITE study were analysed. Five symptoms (cough, dyspnoea, bronchopulmonary haemorrhage, chest wall pain, dysphagia) were evaluated both before and after radiotherapy. Agreement between healthcare professionals and people with lung cancer was quantified using Gwet's-AC2 coefficient. The influence of clinical variables, comorbidities, and quality-of-life outcomes on agreement was examined through stratified analyses. Results: We found varying levels of agreement between healthcare professionals and people with lung cancer. Bronchopulmonary haemorrhage and dysphagia exhibited very good agreement (meanAC2 > 0.81), while cough and chest wall pain showed substantial agreement (meanAC2 = 0.64 and 0.76, respectively). Dyspnoea had the lowest agreement (meanAC2 = 0.59), with prior chemotherapy significantly reducing agreement levels. Chronic obstructive pulmonary disease (COPD) and early cancer stages also contributed to discrepancies in dyspnoea assessments. Regarding quality-of-life, the most relevant factor was fatigue, which reduced agreement in the assessment of dyspnoea (AC2 = 0.55 vs 0.70), dysphagia (AC2 = 0.48 vs 0.69), cough (AC2 = 0.58 vs 0.82), and chest wall pain (AC2 = 0.77 vs 0.91). Conclusions: Our findings indicate strong alignment between healthcare professionals’ and people with lung cancer evaluations of observable treatment-related symptoms, but less consistency for subjective symptoms such as dyspnoea. Factors such as prior chemotherapy, COPD, and cancer stage should be considered when interpreting symptom assessments. Furthermore, our study underscores the importance of integrating quality-of-life considerations, particularly fatigue, into symptom evaluations to mitigate potential biases in symptom perception.
KW - Correlation measures
KW - Fatigue
KW - Lung cancer
KW - Patient reported outcome measures
KW - Quality of life
KW - Radiation effects
KW - Symptom assessment
U2 - 10.1016/j.lungcan.2024.108072
DO - 10.1016/j.lungcan.2024.108072
M3 - Article
SN - 0169-5002
VL - 199
JO - Lung Cancer
JF - Lung Cancer
M1 - 108072
ER -